3/31/2026
Eli Lilly Invests $6.3 Billion on Sleep Science with Centessa Pharmaceuticals Acquisition
Eli Lilly (NYSE: LLY) is making one of its boldest neuroscience moves yet, announcing a definitive agreement to acquire clinical-stage biotech Centessa Pharmaceuticals (Nasdaq: CNTA) in a deal valued at up to $47.00 per share — representing a total potential equity value approaching $7.8 billion when contingent payments are included.
0
3 min read